Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 41, Issue 12, Pages 1023-1037Publisher
CELL PRESS
DOI: 10.1016/j.tips.2020.09.011
Keywords
-
Categories
Funding
- Fresco Institute Network Research Program (FI-NRP), Fresco Network of Excellence Italy Sites
Ask authors/readers for more resources
Neuroinflammatory and neurodegenerative diseases are characterized by the interplay of a number of molecular pathways that can be assessed through biofluids, especially cerebrospinal fluid and blood. Accordingly, the definition and classification of these disorders will move from clinical and pathological to biological criteria. The consequences of this biomarker-based diagnostic and prognostic approach are highly relevant to the field of drug development. Indeed, in view of the availability of disease-modifying drugs, fluid biomarkers offer a unique opportunity for improving the quality and applicability of results from clinical trials. Herein, we discuss the benefits of using fluid biomarkers for patient stratification, target engagement, and outcome assessment, as well as the most recent developments in neuroinflammatory and neurodegenerative diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available